GSK has announced that the US FDA has accepted for priority review a supplemental New Drug Application for gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea in patients aged 12 and over...
GSK will receive a $370 million upfront payment, plus 1% royalties on US sales of certain mRNA vaccines by BioNTech and Pfizer, following a settlement linked to CureVac’s recent agreement with BioNTech...
GSK plc has entered agreements with Hengrui Pharma to develop up to 12 innovative medicines, including an exclusive worldwide licence (ex‑China) for HRS‑9821, a potential best‑in‑class PDE3/4 inhibitor for COPD, for $500 million in upfront fees and up to $12 billion in milestone payments...
The US FDA has accepted GSK’s application to extend Arexvy to adults aged 18-49 at increased risk of severe RSV infection, supported by positive Phase IIIb data; a decision is expected in H1 2026...
GSK's RSV vaccine has gained regulatory approval in Japan for adults aged 18-49 at increased risk, expanding protection against this common respiratory virus...
GSK's RSV vaccine, Arexvy, is set for expanded use in adults 18+, following EMA's acceptance. This breakthrough addresses a critical need in respiratory health...
GSK has announced that the US FDA has accepted for priority review a supplemental New Drug Application for gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea in patients aged 12 and over...
GSK will receive a $370 million upfront payment, plus 1% royalties on US sales of certain mRNA vaccines by BioNTech and Pfizer, following a settlement linked to CureVac’s recent agreement with BioNTech...
GSK plc has entered agreements with Hengrui Pharma to develop up to 12 innovative medicines, including an exclusive worldwide licence (ex‑China) for HRS‑9821, a potential best‑in‑class PDE3/4 inhibitor for COPD, for $500 million in upfront fees and up to $12 billion in milestone payments...
The US FDA has accepted GSK’s application to extend Arexvy to adults aged 18-49 at increased risk of severe RSV infection, supported by positive Phase IIIb data; a decision is expected in H1 2026...
GSK's RSV vaccine has gained regulatory approval in Japan for adults aged 18-49 at increased risk, expanding protection against this common respiratory virus...
GSK's RSV vaccine, Arexvy, is set for expanded use in adults 18+, following EMA's acceptance. This breakthrough addresses a critical need in respiratory health...
